64
Participants
Start Date
July 31, 2003
Primary Completion Date
July 31, 2004
Study Completion Date
July 31, 2004
dronabinol
10 - 20 mg
ondansetron
8 - 16 mg
dronabinol/ondansetron
10 - 20 mg/8 - 16 mg
placebo
placebo
Site 970, Tucson
Site 950, Anaheim
Site 925, Fountain Valley
Site 913, Greenbrae
Site 909, Los Angeles
Site 908, Pomona
Site 943, Rancho Mirage
Site 932, Boynton Beach
Site 924, Hollywood
Site 940, Lakeland
Site 921, New Port Richey
Site 929, New Port Richey
Site 933, Ormond Beach
Site 922, Marietta
Site 928, Harvey
Site 914, Orland Park
Site 926, Skokie
Site 946, Springfield
Site 956, Terre Haute
Site 905, Southfield
Site 916, Fergus Falls
Site 937, Greenwood
Site 958, St Louis
Site 904, Missoula
Site 919, Little Silver
Site 920, Voorhees Township
Site 948, Brooklyn
Site 953, Brooklyn
Site 910, The Bronx
Site 949, Valhalla
Site 947, Wilmington
Site 902, Bismarck
Site 942, Fargo
Site 944, Columbus
Site 934, Oklahoma City
Site 931, Philadelphia
Site 906, Pittsburgh
Site 918, Charleston
Site 923, North Charleston
Site 917, Chattanooga
Site 939, Chattanooga
Site 915, Texarkana
Site 951, Arlington
Solvay Pharmaceuticals
INDUSTRY